Chronic pelvic pain (CPP) is defined as constant or intermittent lower, cyclical or non-cyclical abdominal pain of at least six months’ duration. In the United Kingdom, over 1 million women suffer from CPP, with an estimated annual healthcare cost above £150 million. The aetiology of CPP is unknown in up to 50% of women, and in the remainder, the symptoms of CPP is associated with endometriosis, pelvic adhesions, irritable bowel syndrome or painful bladder syndrome. CPP is often accompanied by painful periods, pain during sexual intercourse and defaecation. Fatigue, sleep disturbances and depression are also common among this group of women. CPP asserts a heavy emotional, social and economic burden. Standard treatments such as hormonal and analgesic regimens are often associated with unacceptable side effects, even if helpful for the pain, underlining an urgent need for a satisfactory treatment. The meridian balanced method (BM) electro-acupuncture (EA) treatment (acupuncture needling + traditional Chinese medicine health consultation [TCM HC]) may be effective in managing CPP symptoms. Thus, I have completed a pilot study comprising of a three-armed randomised controlled trial (RCT), using a mixed methods research (MMR) approach, to assess the feasibility of a future large-scale RCT to determine the effectiveness of the meridian BMEA treatment on CPP in women. My hypothesis is that it is feasible to conduct such a large-scale RCT for CPP in women. The primary objectives were to determine recruitment and retention rates. The secondary objectives were to evaluate the, acceptability of the methods of recruitment, randomisation, interventions and assessment tools and any signals of effectiveness of the interventions. Thirty (30) women with CPP were randomised into three groups: BMEA treatment, TCM HC, or National Health Service standard care (NHS SC) group. The effects of my interventions were assessed by validated pain, physical and emotional functioning questionnaires, completed at weeks 0, 4, 8 and 12 of the study. Semi-structured telephone interviews and focus group discussions to explore participants’ experience of the study were conducted. Of the 59 women who were referred to the study, 30 women (51%) were randomised. There was a statistically significant difference in retention rates between the three groups. The retention rates were 80% (95% CI 74-96), in the BMEA treatment group, 53 % (95% CI 36- 70) in the TCM HC group and 87% (95% CI 63-90) in the NHS SC group. (Chi-square test, p=0.08) The attendance rates of the BMEA treatment group were 90% compared to 56% in the TCM HC group. There was a statistically significant difference (Mann-Whitney test, p=0.023) in attendance between the two intervention groups. Telephone interviews regarding the acceptability of the methods of recruitment, randomisation, assessment tools and interventions were positive. No adverse effects that were directly related to BMEA treatments were reported or observed. A higher proportion of the BMEA treatment group achieved clinical significance in the VAS-pain, BPI-pain severity, interference, and sleep scores, when compared to the other two groups. Due to small sample sizes, there was insufficient power to show statistically significant difference. (Fishers Exact Test, p=1.0) Analyses of the questionnaire data per group showed statistically significant differences in the following: the BMEA treatment group experienced less in pain at weeks 4 (p=0.01) and 8 (p=0.005); less helplessness (p=0.03) and their anxiety and depression scores declined at week 4 (p=0.04). The NHS SC group also reported less pain at week 4 (p=0.04). However, this group scored higher in anxiety and depression at weeks 8 and 12 (p=0.04). No statistically significant differences were achieved between the three groups at baseline, weeks 4, 8 and 12 in all scores. The therapeutic benefits gained by the TCM HC group were less compared to those of the BMEA treatment group, but better when compared to the NHS SC group. The BMEA treatment and TCM HC groups showed lower scores in anxiety and depression while the NHS SC group showed higher scores in anxiety and depression. The NHS SC group also tended to ruminate and magnify their problems as well as feeling more helpless than the other two groups. The three key themes that emerged from thematic analysis of focus group discussions were the “whole person effects” where participants reported an improvement in pain, sleep and a general sense of wellbeing in the two intervention groups; the “experience of standard care” and “impact of living with CPP”. In conclusion, the results of my pilot study are supportive of the feasibility of a future large-scale study. There were signals of effectiveness of interventions but the sample size was too small to make a definitive conclusion.

No description available.

Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 4 uppsatser.

L’aluminium (Al) est le métal le plus abondant de notre environnement. Il est naturellement présent dans les sols, les roches, les minéraux, l’air, l’eau, et son utilisation pour la fabrication de produits de consommation courante n’a cessé d’augmenter de façon exponentielle dans les pays industrialisés. Durant les dernières décennies, la biodisponibilité de l’Al a fortement augmenté par l’activité humaine et les populations sont exposées quotidiennement à de multiples sources et doses d’Al, notamment par la voie orale. En se basant sur la description des effets toxiques et délétères de l’Al dans diverses pathologies ainsi que sur les doses d’Al ingérées, nous avons montré que l’Al pouvait participer à l’aggravation de l’inflammation intestinale, diminuer la cicatrisation muqueuse et le renouvellement cellulaire (Pineton de Chambrun et al., 2014).Dans le but de comprendre les mécanismes par lesquels l’Al perturbait l’épithélium intestinal, nous avons évalué la toxicité de l’Al sur la cellule épithéliale intestinale. Nous avons montré dans cette étude que l’Al diminuait la viabilité cellulaire, favorisait l’apoptose et perturbait le cycle cellulaire. L’Al avait également des effets pro-carcinogènes et pro-inflammatoires sur les cellules épithéliales intestinales. Ainsi, nous avons démontré que l’Al pouvait avoir des effets toxiques sur la muqueuse intestinale.Nous avons ensuite étudié les effets de l’Al sur la sensibilité viscérale chez le rongeur. Nous avons montré que l’ingestion d’une dose d’Al cohérente avec l’exposition humaine induisait une augmentation de la sensibilité viscérale chez le rat et la souris. Cette hypersensibilité induite par l’Al était persistante et exacerbée lors d’une nouvelle intoxication, indiquant ainsi qu’il n’y a pas de phénomène de tolérance. De plus, les femelles étaient plus affectées par l’hypersensibilité induite par l’Al que les mâles. Nous avons montré que les mécanismes impliquaient une augmentation de la perméabilité et étaient dépendants de la dégranulation des mastocytes et du récepteur aux protéases 2. Ces résultats sont pertinents avec la description des mécanismes observés dans la pathogénèse du syndrome de l’intestin irritable (SII). En effet, les malades présentent le plus souvent une hypersensibilité viscérale, une augmentation de la perméabilité intestinale, une altération du microbiote et une inflammation intestinale à bas grade. Les causes de cette maladie sont inconnues mais les facteurs environnementaux sont fortement suspectés. Ainsi, l’Al pourrait être un nouveau facteur de risque environnemental impliqué dans le développement du SII.En conclusion, ces résultats nous ont permis de démontrer la toxicité de l’Al sur le tube digestif et de mettre en avant un nouveau facteur de risque environnemental dans la physiopathologie des maladies intestinales telles que les maladies inflammatoires chroniques de l’intestin et le syndrome de l’intestin irritable. / Aluminium (Al) is the most abundant metal in our environment. Al naturally occurs in soils, rocks, minerals, air, water and its use in consumer products increase exponentially in industrialized countries. During last decades, human activities led to an increase in the bioavailability of Al and populations are exposed daily to multiple sources and doses of Al, including the oral route. Based on the description of toxic and deleterious effects of Al in various pathologies as well as ingested doses of Al, we showed that Al could participate in the exacerbation of intestinal inflammation, decrease mucosal healing and cell renewal (Pineton de Chambrun et al., 2014).In order to understand the mechanisms involved in the perturbations of the intestinal epithelium, Al toxicity was evaluated on intestinal epithelial cells. This study showed that Al decrease cell viability, promote apoptosis and disturb cell cycle. Al had also pro-tumorigenic and pro-inflammatory effects on intestinal epithelial cells. Thus, we demonstrated that Al could promote toxic effects on intestinal mucosa.Then, we evaluated the effects of Al on visceral sensitivity in rodents. We have demonstrated that currently ingested amounts of Al, in humans, induced in mice and rats a dose dependent increase of colorectal sensitivity. Al-induced hypersensitivity persists over time so that intoxication was arrested, and appears again when Al intoxication resumes, dismissing any tolerance phenomenon. Moreover, female gender was more affected by Al-induced hypersensitivity than male gender. Mechanisms involved an increased permeability and were dependent on mast cell degranulation and protease activated receptor 2. These results are relevant to the mechanisms observed in the pathogenesis of irritable bowel syndrome (IBS). Indeed, patients usually exhibit visceral hypersensitivity, increased permeability, impaired microbiota and low inflammation degree of the gastrointestinal tract. Causes of the disease remain unknown but environmental factors are strongly suspected to be involved in the pathogenesis. Thus, Al could be a new environmental risk factor involved in the development of IBS.In conclusion, these results demonstrate the toxicity of Al on the digestive tract and highlight a new environmental risk factor in the physiopathology of intestinal diseases such as inflammatory bowel diseases and irritable bowel syndrome.

Made available in DSpace on 2015-05-14T13:00:02Z (GMT). No. of bitstreams: 1 arquivototal.pdf: 1170808 bytes, checksum: 7b299ea2ca71a584be9ecd4dbd10364c (MD5) Previous issue date: 2014-02-14 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES / The irritable bowel syndrome (IBS) is defined as the presence of continuing or recurrent abdominal pain or discomfort and it is associated with altered bowel habit. Its pathophysiology involves the following aspects: genetic variables, changes in gut motility and visceral sensitivity, psychosocial factors, in addition to inflammatory and infectious processes. The treatment is based on dietary guidance and change in lifestyle. The use of drugs is indicated in symptomatic stages of IBS. The growing interest of patients for complementary and alternative medicine has been observed in recent years. Panax ginseng C.A. Meyer has been used for centuries in oriental medicine. Experimental studies have demonstrated the antinociceptive action of this herbal medicine on calcium and sodium channels, as well as on primary sensory neurons. The study aimed to: conduct phase II clinical trial with Panax ginseng CA Meyer in patients with IBS; contribute to the study of the pharmacological effects of Panax ginseng C.A. Meyer; evaluate the therapeutic efficacy of Panax ginseng C.A. Meyer in abdominal pain control in patients with IBS; and observe the adverse effects. Twenty-six patients were selected by means of the inclusion criteria for the study and they were divided into two groups. A clinical double-blind, randomized, prospective and experimental trial was conducted for eight weeks, comparing the action of dry extract of Panax ginseng (300 mg / day) with trimebutine (600 mg / day). Abdominal pain was assessed using the Likert scale. Patients were assessed at four visits and the results were analyzed using the Mann-Whitney and Friedman tests, with a significance level of p < 0.05. Twenty- four patients completed the study, being 87.50% female and mean age of 47.41 years. There was a relative homogeneity among patients with regard to sex, age and duration of symptoms. All patients, before beginning treatment with Panax ginseng and trimebutine, had negative scores for the Likert scale values. There was improvement in abdominal pain, through this scale, in patients who used Panax ginseng. This group started from a median basal of -5 to 2.5, 3 and 5 in the 1st, 4th and 8th weeks of treatment, respectively, with a statistically significant difference. Similar results were achieved in the group that used the trimebutine. The only adverse effect observed was the occurrence of headache in two patients (16.66%) in the group that used the herbal. Panax ginseng C.A. Meyer was effective in the control of abdominal pain in IBS patients, analogous to trimebutine, and may be used in future studies, with the prospect of a phase III clinical trial. / A síndrome do intestino irritável (SII) é definida pela presença de dor ou desconforto abdominal contínuo ou recorrente, estando associada com alterações do hábito intestinal. Sua fisiopatologia envolve os seguintes aspectos: variáveis genéticas, alterações da motilidade intestinal e da sensibilidade visceral, fatores psicossociais, além de processos inflamatórios e infecciosos. O tratamento é baseado em orientação dietética e na mudança do estilo de vida. O uso de fármacos é indicado nas fases sintomáticas da SII. Tem sido observado o crescente interesse dos pacientes pela medicina alternativa e complementar, nos últimos anos. O Panax ginseng C.A. Meyer é utilizado há séculos pela medicina oriental. Estudos experimentais demonstraram a ação antinociceptiva desse fitoterápico sobre os canais de cálcio e de sódio, assim como sobre os neurônios sensoriais primários. O estudo teve como objetivos: realizar ensaio clínico de fase II com o Panax ginseng C.A. Meyer em pacientes com SII; contribuir para o estudo dos efeitos farmacológicos do Panax ginseng C.A. Meyer; avaliar a eficácia terapêutica do Panax ginseng C.A. Meyer no controle da dor abdominal em pacientes com SII; observar os efeitos adversos. Foram selecionados vinte e seis pacientes, através de critérios de inclusão para a pesquisa, sendo divididos em dois grupos. Foi realizado um estudo clínico, duplo cego, randômico, prospectivo e experimental por oito semanas, comparando a ação do extrato seco do Panax ginseng (300 mg/dia) com a trimebutina (600 mg/dia). A dor abdominal foi avaliada através da escala de Likert. Os pacientes foram avaliados em quatro consultas e os resultados foram analisados através dos testes de Mann-Whitney e Friedman, com nível de significância quando p<0,05. Vinte e quatro pacientes concluíram o estudo, sendo 87,50% do sexo feminino e média de idade de 47,41 anos. Ocorreu uma relativa homogeneidade nos grupos de estudo no que se refere ao sexo, idade e duração dos sintomas. Todos os pacientes, antes do início dos tratamentos com Panax ginseng e trimebutina, apresentavam os valores negativos para os escores na escala de Likert. Houve melhora da dor abdominal, nos pacientes que utilizaram o Panax ginseng. Esse grupo partiu de uma mediana basal de -5 para 2,5, 3 e 5, na 1ª., 4ª. e 8ª. semanas de tratamento, respectivamente, com diferença estatisticamente significativa. O efeito adverso observado foi a ocorrência de cefaleia em dois pacientes (16,66%), no grupo que usou o fitoterápico. O Panax ginseng C.A. Meyer foi eficaz no controle da dor abdominal em pacientes com SII, de modo análogo à trimebutina, podendo ser utilizado em novos estudos, com a perspectiva de um ensaio clínico de fase III.

Introdução: A má digestão de lactose detectada por testes respiratórios é bastante comum em pacientes com síndrome do intestino irritável (SII), e alguns pacientes com SII referem exacerbar seus sintomas após a ingestão de leite e produtos lácteos. A fim de uma melhor percepção sobre este tema, este trabalho investigou os efeitos da dieta isenta de lactose em pacientes com SII e teste respiratório de hidrogênio para avaliação da digestão de lactose normal ou anormal. Objetivo: Avaliar os efeitos de uma dieta isenta de lactose em pacientes de SII com ou sem teste positivo para má digestão de lactose (teste respiratório). Métodos: 80 pacientes atendidos no Ambulatório de Doenças Funcionais Intestinais do Serviço de Gastroenterologia Clínica do HCFMUSP foram recrutados para o estudo prospectivo. Os pacientes preencheram os critérios de Roma III para SII. Durante o ensaio do teste respiratório de hidrogênio todos os sintomas desencadeados pela ingestão de lactose foram anotados. Ambos os grupos de pacientes com e sem má digestão de lactose, foram submetidos a uma dieta isenta de lactose durante 4 semanas. A história prévia de intolerância ao leite e derivados também foi documentada. No final de cada semana, os pacientes foram solicitados a informar a respeito dos seus sintomas, e os resultados, foram devidamente marcados de acordo com a sua intensidade (Escore Global). Além disso, foi também obtida a Avaliação Global do Paciente no final do tratamento (AFG). Resultados: 33/80 (41,25%) pacientes com SII tiveram um teste respiratório anormal para a má digestão de lactose, e 47/80 dos pacientes (58,75%) com SII tiveram um teste respiratório normal (ns). Não houve diferença significativa na freqüência de queixas de intolerância prévia ao leite e derivados em ambos os grupos. No entanto, mais pacientes no grupo com má digestão de lactose referiram sintomas durante o teste respiratório com 25 g de lactose do que o grupo com digestão normal a lactose (p <0,001). Ambos os grupos igualmente melhoraram após uma dieta isenta de lactose, quando avaliados pelo escore geral e pelo AFG. Conclusões: Ambos os grupos de pacientes com SII, com e sem má digestão de lactose, melhoraram após 4 semanas de dieta isenta de lactose. Os nossos resultados sugerem que outros mecanismos, além da intolerância à lactose, devem ser levados em conta para explicar a melhora com uma dieta isenta de lactose em pacientes com SII / Introduction: Lactose intolerance detected by respiratory tests is rather common in patients with irritable bowel syndrome(IBS); also, some IBS patients refer their symptoms exacerbate after ingestion of milk and dairy products. In order to gain some insight into this topic we investigated the effects of a lactose-free diet in IBS patients with and without lactose intolerance diagnosed by means of the hydrogen respiratory test. Objective: To evaluate the effects of a lactose-free diet in IBS patients with and without lactose intolerance. Methodos: 80 patients who attended the outpatient clinic at the University of São Paulo School of Medicine Hospital, Brazil, were recruited for this prospective study. Patient met the Rome III criteria for IBS. During the hydrogen respiratory test all the symptoms triggered by lactose ingestion were taken down. Both groups of patients, with and without lactose intolerance, were submitted to a lactose-free diet for 4 weeks. Previous history of milk/dairy products intolerance was documented. At the end of each week, patients were asked to inform about their symptoms and the results were duly scored according to their intensity (Global Score). Also, the Patient Final Global Evaluation of the Treatment (PFGET) was obtained as well. Results: 33/80 (41.25%) IBS patients had an abnormal respiratory test for lactose intolerance; 47/80 (58.75%) IBS patients had a normal respiratory test (n.s.). There was no significant difference in the frequency of previous complaints after milk/dairy products ingestion in both groups. However, more patients in the lactose intolerant group referred symptoms during the respiratory test with 25 g of lactose than the lactose tolerant group (p<0,001). Both groups similarly improved after a lactose-free diet when evaluated by both the Global Score and the PFGET. Conclusions: Both groups of IBS patients, with and without lactose intolerance, improved after a 4-week lactose-free diet. Our results suggest that other mechanisms, in addition to lactose intolerance, should be taken into account to explain why IBS patients improve with a lactose-free diet

A Psicossomática se constituiu como campo de saber tendo como uma de suas principais influências as contribuições de Freud a respeito da relação entre mente e corpo. Desde Alexander até os teóricos de orientação psicanalítica mais atuais, a questão da somatização, no sentido lato, vem sendo discutida e, apesar das divergências teóricas, o que sempre está em pauta nas somatizações é o comprometimento da capacidade de simbolização do sujeito frente às vicissitudes da vida. Essa mesma característica é central nas neuroses atuais, de forma que há possível associação entre a somatização e a neurose atual. Dessa forma, os objetivos principais são verificar se esse comprometimento na capacidade de simbolização está presente e como se apresenta em sujeitos com somatização e em sujeitos com neurose atual. Para se realizar o estudo, foram eleitos dois transtornos que são representantes das categorias acima citadas: nas somatizações, vamos pensar a partir dos transtornos somatoformes, utilizando a subcategoria dos transtornos neurovegetativos somatoformes, elegendo a Síndrome do Intestino Irritável; e nas Neuroses Atuais, o Transtorno de Pânico (Neurose de Angústia). Os resultados vão permitir uma comparação, a partir da capacidade de simbolização, entre essas duas categorias e a verificação de maiores relações entre ambas, assim como relação com alexitimia, pensamento operatório e personalidade tipo A, características geralmente associadas a esses tipos de pacientes. A pesquisa foi feita a partir de estudos bibliográficos e psicodiagnóstico dos sujeitos da pesquisa, com entrevista semi-dirigida, aplicação de pranchas do TAT, escalas de alexitimia (TAS e OAS) e entrevista para Personalidade tipo A. Foram utilizados três sujeitos com Síndrome do Intestino Irritável e dois com Transtorno de Pânico. Nos sujeitos da pesquisa, quando aparece comprometimento na capacidade de simbolização, as histórias no TAT são mais curtas, descritivas, concretas, com introdução de nenhum ou poucos elementos externos à prancha, dificuldade na resolução de conflito, personagens pouco integrados, ausência de referências afetivas ou afetividade negativa, prejuízo da integração do ego, com predomínio de pensamento do tipo operatório. Pensar o comprometimento da capacidade de simbolização em pacientes com somatização a partir do pensamento operatório faz sentido, visto que os sujeitos apresentaram tal forma de pensamento, embora apresentem variações significativas na intensidade e frequência de funcionamento metal do tipo operatório. Contudo, definir o paciente com somatização ou com neurose atual necessariamente como alexitímico é insuficiente, visto que nem todos apresentaram tal característica. Pela análise de dados dos sujeitos, há pacientes os quais o comprometimento na capacidade de simbolização funciona como defesa psíquica diante da angústia, de forma a prejudicar a integração do ego em razão de manter um funcionamento mental mais estável; e há os que esse comprometimento é característico do funcionamento mental. Compreendendo o funcionamento psicológico que há por trás das somatizações o comprometimento da capacidade de simbolização e as formas como se configura na dinâmica psíquica do sujeito como defesa psíquica ou como característica do funcionamento mental pode-se estabelecer métodos de abordagens e técnicas psicoterápicas mais eficientes e condizentes com pacientes com somatizações / The Psychosomatic constituted itself as a field of knowledge has as one of his major influences the contributions of Freud on the relationship between mind and body. From Alexander to the psychoanalytic theoristis more current, the issue of somatization in the broadest sense, has been discussed and, despite the theoretical differences, is always at hand in somatization the impaired ability of symbolization of the subject facing the vicissitudes of life. This same feature is central to the actual neurosis, so that there is a possible association between somatization and actual neurosis. Thus, the main objectives are to determine if that impairment in the ability of symbolization is present and how shown in subjects with somatization and in subjects with actual neurosis. To perform the study, two disorders that are elected representatives of the categories mentioned above: in somatization, we think from the somatoform disorders, using the subcategory of somatoform autonomic dysfunction, electing the Irritable Bowel Syndrome, and in Actual Neurosis, the Panic Disorder (Anxiety Neurosis). The results will allow a comparison, from the capacity for symbolization, between these two categories and the verification of relations between the two, as well as compared with alexithymia, operational thinking and type A personality, characteristics associated with these types of patients. The survey was conducted from bibliographic studies and psychodiagnostic research subjects, with semi-directed interview, application of TAT cards scales of alexithymia (TAS and OAS) and interview for Type A Personality. We used three subjects with Irritable Bowel Syndrome and two with Panic Disorder. In the research subjects, when it appears impairment in the ability of symbolization, the TAT stories are shorter, descriptive, concrete, with few or no introduction of foreign elements to the board, difficulty in conflict resolution, low integrated characters, no references affective or negative affectivity, impaired ego integration, with a predominance of thought like operatory. Thinking the impaired ability of symbolization in patients with somatization from operational thinking makes sense, because the subjects had this way of thinking, although they have shown significant variations in intensity and frequency of operation of the metal type operatory. However, defining the patient with somatization or actual neurosis necessarily as alexithymic is insufficient, since not everyone had such a feature. For the data analysis of the subjects, there are patients who compromise the ability to symbolizing as psychic defense in the face of anguish, in order to undermine the integration of the ego to maintain a more stable mental functioning, and there are that this commitment is characteristic of mental functioning. Understanding the psychological functioning that is behind the somatization - the impaired ability of symbolization - and the ways to configure the psychic dynamics of the subject - such as defense or as a psychological characteristic of mental functioning - can establish methods of psychotherapeutic approaches and techniques more efficient and consistent with patients with somatization

Na Psicossomática, dentro do modelo biopsicossocial, entende-se que respostas psicológicas a condições de vida podem interagir com fatores somáticos existentes, alterando a susceptibilidade e manifestação da doença, o que se mostra evidente nas somatizações, como na Síndrome do Intestino Irritável (SII), onde há alteração da motilidade intestinal e no formato das fezes, acompanhada de dores abdominais. O funcionamento mental associado às somatizações, no qual a pessoa apresenta dificuldade em relacionar o adoecimento com seu universo psicológico, é que a capacidade de simbolização, ou seja, a construção de representações mentais para o alívio do estado emocional, é afetada, cronificando as alterações fisiológicas correspondentes. O objetivo da pesquisa foi verificar se o atendimento clínico psicológico, baseado na técnica da Psicoterapia Breve Operacionalizada (PBO), com ênfase na promoção da capacidade de simbolização em relação a determinadas questões significativas, pode contribuir para a melhora dos sintomas no quadro clínico de pacientes com SII. O método utilizado na pesquisa foi o clínico-qualitativo, a partir do estudo de caso de duas pacientes adultas, com o diagnóstico principal de transtorno neurovegetativo somatoforme, portadoras de SII. A intervenção psicológica foi estruturada em três fases: 1) psicodiagnóstico, composto por entrevista semi-dirigida, Sistema Diagnóstico Adaptativo Operacionalizado (SISDAO) e Teste de Apercepção Temática (TAT), questionário de avaliação clínica da SII; 2) psicoterapia breve, em doze sessões; 3) reavaliação após seis meses. A capacidade de simbolização da primeira participante era comprometida fundamentalmente relacionada à sua dificuldade em lidar com a perda da mãe quando criança, num luto não elaborado. Apresentava dores abdominais forte, a cada dois ou três dias, evacuando uma vez ao dia e quando em crise, duas ou três vezes por dia. A segunda participante apresentou uma capacidade de simbolização que passava a ser comprometida quando o conflito entre o desejo de ser aceita por sua família, em especial sua mãe, e o de rompimento tornava-se insuportável. Apresentava dores moderada, a cada cinco dias, evacuando quatro vezes ao dia e, quando em crise, seis vezes ao dia. A intervenção clinico psicológica em pacientes com SII, baseada na técnica da PBO, com elaboração da demanda psicológica e das questões significativas que comprometiam a capacidade de simbolização, possibilitou a elaboração psicológica dos estados emocionais que estariam influenciando os sintomas da SII, de forma que contribuiu para a melhora do quadro clínico das participantes. Após seis meses da psicoterapia, a primeira participante apresentou dores fracas a cada cinco dias, frequência única de evacuação por dia, não apresentou crises. A segunda participante estava evacuando uma a duas vezes por dia, dores fracas a cada cinco dias e crises ocorriam em menor frequência. O modelo de intervenção mostrou-se vantajoso para as participantes da pesquisa, de forma que seu uso no tratamento clinico psicológica para pacientes com SII, levando em consideração as especificidades do funcionamento mental associado às somatizações, apresenta-se promissor / In Psychosomatics, within the biopsychosocial model, it is understood that psychological responses to living conditions may interact with existing somatic factors, altering the susceptibility and manifestations of diseases, which is evidenced in somatizations, such as the case of Irritable Bowel Syndrome (IBS), where there is altered intestinal motility and stool format, accompanied by abdominal pain. The mental functioning associated with somatizations, in which a person presents difficulties in associating the illness to their psychological universe, that is, the capacity of symbolization, i.e. the construction of mental representations for the relief of the emotional state is affected, cronifying the physiological changes. The research objective was to determine whether psychological clinical care, based on the technique of Operationalized Brief Psychotherapy (OBP), with emphasises on promoting symbolization capacity regarding certain significant issues, can contribute to the improvement of symptoms in clinical condition of patients with IBS. The method used in the study was the clinical-qualitative, from the case study of two female adult patients with primary diagnosis of somatoform autonomic disorder, suffering from IBS. Psychological intervention was structured in three phases: 1) psychodiagnosis, composed of semi-directed interview, Operationalized Adaptive Diagnostic System (OADS) and Thematic Apperception Test (TAT), questionnaire of clinical evaluation of IBS; 2) brief psychotherapy split in twelve sessions; 3) re-evaluation after six months. The symbolization capacity of the first participant was compromised primarily because of her difficulty dealing with the loss of her mother when a child, in a non-elaborated mourning. The patient presented strong abdominal pains, every two or three days, evacuating once a day and when in crisis, two or three times a day. The second participant presented a symbolization capacity that began to be compromised when the conflict between the desire to be accepted by her family, especially her mother, and the disruption became unbearable. She felt moderate pain, every five days, evacuating four times a day, and when in crisis, six times a day. Psychological clinical intervention in patients with IBS, based on the technique of OADS, with development of psychological demand and significant issues that compromised the capacity of symbolization, allowed the psychological development of emotional states that would influence the symptoms of IBS, so it contributed to the improvement of the clinical condition of the participants. After six months of psychotherapy, the first participant presented weak pains every five days, single daily stool frequency, no crisis. The second participant was evacuating once or twice a day, felt weak pains every five days and crisis occurred less frequently. The intervention model was advantageous to the participants, so that its use in clinical psychological treatment for IBS patients presents promising, taking into account the specifics of mental functioning associated with somatization

The present study sought to determine whether a dietary and multi-element psychological treatment (DMPT) approach in combination with standard medical treatment would offer a more efficacious therapeutic package to irritable bowel syndrome (IBS) patients than would standard medical treatment (SMT) employed alone. The DMPT group (N = 19) received a stress management training package for a 2 week period consisting of relaxation training, imagery, and bowel sound biofeedback training via a stethoscope, in addition to instructions to increase their daily consumption of dietary fiber. They also were to continue the implementation of whatever standard medical treatment they were currently receiving, be it a bulking agent, or anti-anxiety, anti-cholinergic, or anti-depressant medications, etc. The SMT group (N = 19) simply received whatever conventional medical treatment they had been prescribed.

Irritable bowel syndrome (IBS) är en av de vanligaste diagnostiserade GI-tillstånden idag och är en störning av gastrointestinalkanalen (GI-kanalen). Det finns inget botemedel mot IBS på grund av att patogenesen är oklar och därför är fokusen symtomlindring vid behandling.  De vanligaste symtom som förekommer är buksmärta, obehag i buk, uppblåsthet, utspänd buk och förändring av avföringens konsistens och frekvens. Patofysiologin är inte fullt klarlagd men en rubbning i tarm-hjärn-axeln kan leda till förändring i GI-rörelser. Neurotransmittorerna noradrenalin och serotonin (5-HT) är troligen viktiga faktorer för patofysiologin kopplad till tarm-hjärn-axeln. Syftet var att undersöka effektiviteten och säkerheten för de antidepressiva läkemedlen vid behandling av IBS. De antidepressiva som undersöktes i arbetet var tianeptin, amitriptylin, escitalopram, venlafaxin, vortioxetin och mirtazapin. De fem artiklarna som användes i detta arbete upptäcktes med hjälp av databaserna Pubmed och Onesearch. Sökord som användes var ”IBS” AND ”antidepressants” och ”IBS” AND ”SSRI”.  Alla antidepressiva visade en signifikant förbättring för livskvalitén hos deltagarna i studierna. Tianeptin, amitriptylin, escitalopram, venlafaxin och mirtazapin undersökte förändring av buksmärta och alla hade en signifikant förbättring förutom escitalopram. Escitalopram jämfördes mot rektal ballongutvidgning vid behandling hos IBS med förstoppning (IBS-C). Ballongutvidgningen visade bättre resultat än escitalopram och denna jämförelse gör det svårt att dra någon slutsats om escitalopram i arbetet. Amitriptylin, tianeptin och mirtazapin undersökte förändring av avföringskonsistensesn och frekvensen och visade en signifikant förbättring hos IBS med diarré (IBS-D). Venlafaxin visade signifikant förbättring för både lös och hård avföringsfrekvens och studerade ingen specifik IBS-grupp. Vortioxetin undersökte alla IBS-grupper och endast förändring av livskvalitén, depression och ångest vilket också gör det svårt att dra slutsats om effekt hos IBS. Det var inga av de depressiva medlen som gav allvarliga biverkningar, dock kan vissa biverkningar tolkas som mer obehagliga än andra. För vissa antidepressiva var det deltagare som avslutade studien på grund av biverkningar. Amitriptylin, tianeptin, venlafaxin vortioxetin och mirtazapin visade alla god effekt och säkerhet. Om effektiviteten ock säkerheten jämförs bland dessa har tianeptin det bästa resultatet. / Irritable bowel syndrome (IBS) is one of the most diagnosed conditions in the gastrointestinal (GI) tract today and is a disorder of the GI tract. There is no cure for IBS, which is probably due to the fact that the pathogenesis is unclear, and therefore the focus has been a symptom-relieving treatment. The most common symptoms that occur are abdominal pain, abdominal discomfort, bloating, distension of the abdomen, and change in the consistency and frequency of the stool. The pathophysiology is not fully understood, but a disorder of the gut-brain axis can lead to a change in GI movements. The neurotransmitters norepinephrine and serotonin (5-HT) are probably important factors for pathophysiology and linked to the gut-brain axis.  The aim was to investigate the effectiveness and safety of antidepressants used in IBS treatment. The antidepressants examined in this literature were tianeptine, amitriptyline, escitalopram, venlafaxine, vortioxetine, and mirtazapine. The five articles on which current litter tour work is based were obtained using the PubMed and OneSearch databases. Keywords used were "IBS" AND "antidepressants" and "IBS" AND "SSRI."  All the antidepressants examined showed a significant improvement in the participants' quality of life in the studies. The studies also examined changes in abdominal pain using tianeptine, amitriptyline, escitalopram, venlafaxine, and mirtazapine. All participants showed a significant improvement and reduced abdominal pain except when ingesting escitalopram. Intake of escitalopram was compared against rectal balloon enlargement as a treatment for IBS with constipation (IBS-C). The balloon expansion showed better results than escitalopram, and this comparison makes it difficult to draw any conclusion about escitalopram and its actual effect in different types of IBS. Amitriptyline, tianeptine, and mirtazapine investigated stool consistency and stool frequency changes and showed a significant improvement in these symptoms in IBS with diarrhea (IBS-D). Venlafaxine showed significant improvement for both loose and hard stool frequency; however, no specific IBS group was studied in this study. When ingesting vortioxetine, all different IBS groups and changes in quality of life, depression, and anxiety were examined, making it difficult to conclude about the effect of the drug in IBS. None of the antidepressant medicines produced severe side effects. However, some side effects can be interpreted as more unpleasant than others, and hence there was some loss during some studies.  Amitriptyline, tianeptine, venlafaxine vortioxetine, and mirtazapine showed good efficacy and safety. If the effectiveness and safety were to be compared between these drugs, tianeptine would be the first choice in treating IBS.